Avβ3 integrin: Pathogenetic role in osteotropic tumors

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 1, 2015, Pages 183-193

  Stucci, Stefania ^a   Tucci, Marco ^a   Passarelli, Anna ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Bone metastasis; Cancer; Multiple myeloma; Target therapy; v 3

Indexed keywords

BEVACIZUMAB; CEDIRANIB; CETUXIMAB; CHEMOKINE; CILENGITIDE; FLUOROURACIL; PACLITAXEL; PROCARBAZINE; SUNITINIB; TEMOZOLOMIDE; VITRONECTIN RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANOIKIS; BONE METASTASIS; BRAIN METASTASIS; CANCER CELL; CANCER STEM CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KAPOSI SARCOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOTROPIC TUMOR; PATHOGENESIS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR GROWTH; BONE DEVELOPMENT; BONE NEOPLASMS; CHEMISTRY; MALE; OSTEOCLAST; PATHOLOGY; PHYSIOLOGY; SECONDARY; SIGNAL TRANSDUCTION;

BONE NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTEGRIN ALPHAVBETA3; MALE; NEOPLASTIC STEM CELLS; OSTEOCLASTS; OSTEOGENESIS; SIGNAL TRANSDUCTION;

EID: 84942197181     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.018     Document Type: Review

References (91)

1. Chambers F., Groom A.C., MacDonald I.C. Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
2. Nguyen D.X., Bos P.D., Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284.
3. Mundy R.G. Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
4. Schneider J.G., Amend S.H., Weilbaecher K.N. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 2011, 48:54-65.
5. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
6. Zaidel-Bar R., Itzkovitz S., Ma'ayan A., Iyengar R., Geiger B. Functional atlas of the integrin adhesome. Nat Cell Biol 2007, 9:858-867.
7. Legate K.R., Fassler R. Mechanisms that regulate adaptor binding to β-integrin cytoplasmic tails. J Cell Sci 2009, 122:187-198.
8. Guo W., Ginacotti F.G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004, 5:816-826.
9. 3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy?. Calcif Tissue Int 2002, 71:293-299.
10. Voura E.B., Ramjeesingh R.A., Montgomery A.M., Siu C.H. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell 2001, 12:2699-2710.
11. Takayama S., Ishii S., Ikeda T., Masamura S., Doi M., Kitajima M. The relationship between bone metastasis from human breast cancer and integrin αvβ3 expression. Anticancer Res 2005, 25:79-83.
12. Nemeth J.A., Cher M.L., Zhou Z., Mullins C., Bhagat S., Trikha M. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003, 20:413-420.
13. Li N., Zhang J.P., Guo S., Min J., Liu L.L., Su H.C., et al. Down-regulation of β3-integrin inhibits bone metastasis of small cell lung cancer. Mol Biol Rep 2012, 39:3029-3035.
14. Rajkumar S.V., Kyle R.A. Angiogenesis in multiple myeloma. Semin Oncol 2001, 28:560-564.
15. Silvestris F., Ciavarella S., De Matteo M., Tucci M., Dammacco F. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?. Oncologist 2009, 14:264-275.
16. Tucci M., De Palma R., Lombardi L., Rodolico G., Berrino L., Dammacco F., et al. Beta(3) integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res 2009, 69:6738-6746.
17. Jin H., Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004, 90:561-565.
18. Mulgrew K., Kinneer K., Yao X.T., Ward B.K., Damschroder M.M., Walsh B., et al. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther 2006, 5:3122-3129.
19. Liu Z., Wang F., Chen X. Integrin alphavbeta 3-targeted cancer therapy. Drug Dev Res 2008, 69:329-339.
20. Posey J.A., Khazaeli M.B., DelGrosso A., Saleh M.N., Lin C.Y., Huse W., et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001, 16:125-132.
21. Gramoun A., Shorey S., Bashutski J.D., Dixon S.J., Sims S.M., Heersche J.N., et al. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J Cell Biochem 2007, 102:341-352.
22. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
23. Gahmberg C.G., Fagerholm S.C., Nurmi S.M., Chavakis T., Marchesan S., Grönholm M. Regulation of integrin activity and signalling. Biochim Biophys Acta 2009, 1790:431-444.
24. McCabe N.P., De S., Vasanji A., Brainard J., Byzova T.V. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007, 26:6238-6243.
25. Mahabeleshwar G.H., Feng W., Reddy K., Plow E.F., Byzova T.V. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 2007, 101:570-580.
26. Somanath P.R., Malinin N.L., Byzova T.V. Cooperation between integrin αvβ3 and VEGFR2 in angiogenesis. Angiogenesis 2009, 12:177-185.
27. Podar K., Anderson K.C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005, 105:1383-1395.
28. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
29. Boettiger D. Mechanical control of integrin-mediated adhesion and signaling. Curr Opin Cell Biol 2012, 24:592-599.
30. Xiong J.P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296:151-155.
31. Takagi J., Petre B.M., Walz T., Springer T.A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002, 110:599-611.
32. Havaki S., Kouloukoussa M., Amawi K., Drosos Y., Arvanitis L.D., Goutas N., et al. Altered expression pattern of integrin alphavbeta3 correlates with actin cytoskeleton in primary cultures of human breast cancer. Cancer Cell Int 2007, 2:7-16.
33. Taverna D., Crowley D., Connolly M., Bronson R.T., Hynes R.O. A direct test of potential roles for β3 and β5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res 2005, 65:10324-10329.
34. Kim M., Carman C.V., Springer T.A. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 2003, 301:1720-1725.
35. Vellon L., Menendez J.A., Lupu R. A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells. Mol Carcinog 2006, 45:795-804.
36. Schwartz M.A., Ginsberg M.H. Networks and crosstalk: integrin signaling spreads. Nat Cell Biol 2002, 4:E65-E68.
37. Streuli C.H., Akhtar N. Signal co-operation between integrins and other receptor systems. Biochem J 2009, 418:491-506.
38. Hannigan G., Troussard A.A., Dedhar S. Integrin-linked kinase. A cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005, 5:51-63.
39. Stupack D.G., Cheresh D.A. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002, 115:3729-3738.
40. Lin H.Y., Sun M., Lin C., Tang H.Y., London D., Shih A., et al. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol 2009, 113:182-188.
41. Cohen K., Flint N., Shalev S., Erez D., Baharal T., Davis P.J., et al. Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αvβ3 integrin in myeloma cells. Oncotarget 2014, 5:6312-6322.
42. Mousa S.A., Lin H.Y., Tang H.Y., Hercbergs A., Luidens M.K., Davis P.J. Modulation of angiogenesis by thyroid hormone and hormone analogues: implications for cancer management. Angiogenesis 2014, 17:463-469.
43. Wietrzyk J., Filip B., Milczarek M., Klopotowska D., Maciejewska M., Dabrowska K., et al. The influence of 1,25-dihydroxyvitamin D3 and 1,24-dihydroxyvitamin D3 on alphavbeta3 integrin expression in cancer cell lines. Oncol Rep 2008, 20:941-952.
44. Lin H.Y., Lansing L., Merillon M., Davis F.B., Tang H.Y., Shih A., et al. Integrin αvβ3 contains a receptor site for resveratrol. FASEB J 2006, 20:1742-1744.
45. Cheresh D.A., Stupack D.G. Integrin-mediated death: an explanation of the integrin-knockout phenotype?. Nat Med 2002, 8:193-194.
46. Aoudjit F., Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J Cell Biol 2001, 152:633-643.
47. Schwartz M.A., Assoian R.K. Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. J Cell Sci 2001, 114:2553-2560.
48. Liu H., Radisky D.C., Yang D., Xu R., Radisky E.S., Bissell M.J., et al. MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits. Nat Cell Biol 2012, 14:567-574.
49. Maubant S., Saint-Dizier D., Boutillon M., Perron-Sierra F., Casara P.J., Hickman J.A., et al. Blockade of alphavbeta3 and alphavbeta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 2006, 108:3035-3044.
50. Reginato M.J., Mills K.R., Paulus J.K., Lynch D.K., Sgroi D.C., Debnath J., et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003, 5:733-740.
51. Desgrosellier J.S., Barnes L.A., Shields D.J., Huang M., Lau S.K., Prévost N., et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 2009, 15:1163-1169.
52. Craig T.J., Guzman M.L., Noble M. Cancer stem cells. N Engl J Med 2006, 355:1253-1261.
53. Taipale J., Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001, 411:349-354.
54. Hurt E.M., Chan K., Serrat M.A., Thomas S.B., Veenstra T.D., Farrar W.L. Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. Stem Cells 2010, 28:390-398.
55. Seguin L., Kato S., Franovic A., Camargo M.F., Lesperance J., Elliott K.C., et al. An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 2014, 16:457-468.
56. Tomaskovic-Crook E., Thompson E.W., Thiery J.P. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 2009, 11:213-223.
57. Galliher A.J., Schiemann W.P. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 2006, 8:R42.
58. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009, 28:15-33.
59. Isaiah J., Fidler The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-458.
60. Byzova T.V., Kim W., Midura R.J., Plow E.F. Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell Res 2000, 254:299-308.
61. Fong Y.C., Liu S.C., Huang C.Y., Li T.M., Hsu S.F., Kao S.T., et al. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2009, 64:263-270.
62. Sun Y.X., Fang M., Wang J., Cooper C.R., Pienta K.J., Taichman R.S. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007, 67:61-73.
63. Tucci M., Stucci S., Savonarola A., Ciavarella S., Cafforio P., Dammacco F., et al. Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation. Br J Haematol 2013, 161:821-831.
64. van der Pluijm G., Sijmons B., Vloedgraven H., van der Bent C., Drijfhout J.W., Verheijen J., et al. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 2001, 159:971-982.
65. Karadag A., Ogbureke K.U., Fedarko N.S., Fisher L.W. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 2004, 96:956-965.
66. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
67. Kaplan R.N., Psaila B., Lyden D. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev 2006, 25:521-529.
68. Bussard K.M., Gay C.V., Mastro A.M. The bone microenvironment in metastasis; what is special about bone?. Cancer Metastasis Rev 2008, 27:41-55.
69. Roodman G.D. Biology of osteoclast activation in cancer. J Clin Oncol 2001, 19:3562-3571.
70. Calvani N., Cafforio P., Silvestris F., Dammacco F. Functional osteoclast-like transformation of cultured human myeloma cell lines. Br J Haematol 2005, 130:926-938.
71. Tucci M., Stucci S., Strippoli S., Dammacco F., Silvestris F. Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?. Oncologist 2011, 16:1040-1048.
72. Eilon G., Mundy G.R. Direct resorption of bone by human breast cancer cells in vitro. Nature 1978, 276:726-728.
73. Drake C.J., Cheresh D.A., Little C.D. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci 1995, 108:2655-2661.
74. Brooks P.C., Strömblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. Anti-integrin alphavbeta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96:1815-1822.
75. Wu H., Beuerlein G., Nie Y., Smith H., Lee B.A., Hensler M., et al. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc Natl Acad Sci U S A 1998, 95:6037-6042.
76. Landen C.N., Kim T.J., Lin Y.G., Merritt W.M., Kamat A.A., Han L.Y., et al. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 2008, 10:1259-1267.
77. Carlos Mas-Moruno, Florian Rechenmacher, Horst, Kessler Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010, 10:753-768.
78. Oliveira-Ferrer L., Hauschild J., Fiedler W., Bokemeyer C., Nippgen J., Celik I., et al. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 2008, 29:27-86.
79. Scaringi C., Enrici R.M., Minniti G. Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets Ther 2013, 9:1079-1095.
80. Albert J.M., Cao C., Geng L., Leavitt L., Hallahan D.E., Lu B. Integrin alphavbeta3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 2006, 65:1536-1543.
81. Reardon D.A., Neyns B., Weller M., Tonn J.C., Nabors L.B., Stupp R. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol 2011, 7:339-354.
82. Tentori L., Dorio A.S., Muzi A., Lacal P.M., Ruffini F., Navarra P., et al. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 2008, 19:1039-1043.
83. Leblond P., Dewitte A., Le Tinier F., Bal-Mahieu C., Baroncini M., Sarrazin T., et al. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction. Anticancer Drugs 2013, 24:818-825.
84. Nabors L.B., Mikkelsen T., Hegi M.E., Ye X., Batchelor T., Lesser G., et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012, 118:5601-5607.
85. Scaringi C., Minniti G., Caporello P., Enrici R.M. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res 2012, 32:4213-4223.
86. Stupp R., Hegi M.E., Neyns B., Goldbrunner R., Schlegel U., Clement P.M., et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28:2712-2718.
87. Manegold C., Vansteenkiste J., Cardenal F., Schuette W., Woll P.J., Ulsperger E., et al. Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Invest New Drugs 2013, 31:175-182.
88. Vermorken J.B., Guigay J., Mesia R., Trigo J.M., Keilholz U., Kerber A., et al. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 2011, 104:1691-1696.
89. Bretschi M., Merz M., Komljenovic D., Berger M.R., Semmler W., Bäuerle T. Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep 2011, 26:843-845.
90. Stupp R., Hegi M.E., Gorlia T., Erridge S.C., Perry J., Hong Y.K., et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15:1100-1108.
91. Tucci M., Stucci S., Silvestris F. Does cilengitide deserve another chance?. Lancet Oncol 2014, 15:e584-e585.